Alvotech Announces Webcast of Full Year 2023 Financial Results on March 21, 2024, at 8:00 am ET
March 05, 2024 16:00 ET
|
Alvotech
REYKJAVIK, Iceland, March 05, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specialized in the development and manufacture of biosimilar medicines for patients...
Alvotech skipar nýjan framkvæmdastjóra gæðamála
February 29, 2024 16:05 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að Christina Siniscalchi hafi verið skipuð tímabundið í stöðu framkvæmdastjóra gæðamála. Christina tekur við af Söndru Casaca, sem lætur af starfi sem liður í...
Alvotech Appoints Interim Chief Quality Officer
February 29, 2024 16:05 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that Christina Siniscalchi will join...
Alvotech gengur að tilboði um sölu hlutabréfa að fjárhæð um 22,8 milljarðar króna (um 166 milljónir dala) á genginu 2.250 krónur (16,41 dalir) á hlut
February 26, 2024 04:25 ET
|
Alvotech
Alvotech (NASDAQ: ALVO) tilkynnti í dag að félagið hafi gengið að tilboði frá hópi fagfjárfesta og viðurkenndra gagnaðila um sölu á 10.127.132 almennum hlutabréfum í félaginu að verðmæti um 22,8...
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024 04:25 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has accepted an offer from...
Alvotech Accepts Offer for the Sale of Shares for a value of approximately USD 166 million at a Purchase price of USD 16.41 (ISK 2,250) per Share
February 26, 2024 04:25 ET
|
Alvotech
REYKJAVIK, Iceland, Feb. 26, 2024 (GLOBE NEWSWIRE) -- Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024 20:15 ET
|
Alvotech
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...
Alvotech hlýtur markaðsleyfi í Bandaríkjunum fyrir Simlandi, líftæknilyfjahliðstæðu við Humira í háum styrk
February 23, 2024 20:15 ET
|
Alvotech
Simlandi (AVT02) verður fyrsta líftæknilyfjahliðstæðan á markaði í Bandaríkjunum sem er útskiptanleg við Humira í háum styrkMarkaðsleyfi með útskiptanleika getur veitt einkarétt til markaðssetningar á...
Alvotech and Teva Announce U.S. Approval of SIMLANDI® (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira®
February 23, 2024 20:15 ET
|
Alvotech
SIMLANDI is the first citrate-free, high-concentration biosimilar to be designated interchangeable to Humira in the U.S. SIMLANDI is the first biosimilar approval under the strategic partnership...
Alvotech Announces Expected Global Market Entry Dates for AVT04 Biosimilar to Stelara® (ustekinumab)
February 15, 2024 06:30 ET
|
Alvotech
Alvotech (NASDAQ: ALVO), a global biotech company specializing in the development and manufacture of biosimilar medicines for patients worldwide, today announced that it has reached settlement...